Used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It functions as a tyrosine kinase inhibitor, targeting the epidermal growth factor receptor (EGFR), which is often overactive in certain cancers. By blocking EGFR signaling, it helps slow or stop tumor growth. Commonly prescribed for patients with specific EGFR mutations, especially in advanced stages of NSCLC. Also used in combination with other chemotherapeutic agents for pancreatic cancer to improve survival rates. Administered orally, allowing for outpatient treatment with relatively manageable side effects compared to traditional chemotherapy.